Yavuz Özışık
- Oncology top 5%
- Cancer Treatment and Pharmacology 14
- HER2/EGFR in Cancer Research 10
- Cancer Risks and Factors 6
- Cancer Diagnosis and Treatment 6
- Cancer Research top 10%
- Breast Cancer Treatment Studies 14
- Obstetrics and Gynecology top 5%
- Reproductive Medicine top 10%
-
- Lymphoma Diagnosis and Treatment 8
- Breast Lesions and Carcinomas 6
-
- Chronic Lymphocytic Leukemia Research 6
- Co-authors
- Kadri AltundağAurelia M. MeloniAvery A. SandbergUrvashi SurtiTaner BabacanMutlu HayranSercan Aksoyİbrahim Güllü
- Partner nations
- TürkiyeUnited StatesCanada
In The Last Decade
Yavuz Özışık
55 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 92
- Oncology 615
- Cancer Research 278
- Obstetrics and Gynecology 127
- Pulmonary and Respiratory Medicine 299
- Reproductive Medicine 75
Countries citing papers authored by Yavuz Özışık
This map shows the geographic impact of Yavuz Özışık's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yavuz Özışık with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yavuz Özışık more than expected).
Fields of papers citing papers by Yavuz Özışık
This network shows the impact of papers produced by Yavuz Özışık. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yavuz Özışık. The network helps show where Yavuz Özışık may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yavuz Özışık, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. | 2017 | 0 |
| 2 | A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer. | 2015 | 5 |
| 3 | 2015 | 40 | |
| 4 | 2014 | 18 | |
| 5 | 2012 | 5 | |
| 6 | 2012 | 130 | |
| 7 | 2011 | 43 | |
| 8 | 2010 | 10 | |
| 9 | 2005 | 8 | |
| 10 | 2002 | 6 | |
| 11 | 1998 | 15 | |
| 12 | 1998 | 25 | |
| 13 | 1995 | 18 | |
| 14 | 1994 | 37 | |
| 15 | 1994 | 16 | |
| 16 | 1994 | 21 | |
| 17 | 1993 | 17 | |
| 18 | 1993 | 56 | |
| 19 | 1993 | 28 | |
| 20 | 1992 | 13 |
About Yavuz Özışık
Yavuz Özışık is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 56 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (14 papers), HER2/EGFR in Cancer Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), Cancer Risks and Factors (6 papers), Cancer Diagnosis and Treatment (6 papers) and Breast Lesions and Carcinomas (6 papers). The work is most often cited by research in Oncology (615 citations), Cancer Research (278 citations) and Obstetrics and Gynecology (127 citations). Yavuz Özışık has collaborated with scholars based in Türkiye, United States and Canada. Frequent co-authors include Kadri Altundağ, Aurelia M. Meloni, Avery A. Sandberg, Urvashi Surti, Taner Babacan, Mutlu Hayran, Sercan Aksoy, İbrahim Güllü, Ömer Dızdar and İbrahim Petekkaya.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.